The Scientific Advisory Board
BRIO’s scientific advisory board (SAB) is made up of 8 internationally renowned researchers covering the five SIRIC disciplines (clinical, biological, epidemiology, public health, human and social sciences) with expertise in the three BRIO programmes, as well as a patient who also researcher (in a different molecular biological field). The role of the SAB is to provide an expert opinion on BRIO‘s research strategy and results. Brio’s progress is presented to the SAB once a year.
Presentation of the 9 members of the SAB:
Prof. David Cameron
Clinical Director and Chair of Oncology,
Cancer Research
Edinburgh, UK
Prof. Stephan Sleijfer
Head of department, Medical Oncology,
Erasmus MC Rotterdam
Rotterdam, Netherlands
Dr Valery Krizhanovsky
Group Head – cellular senescence in tissue damage,
cancer and aging, Weizmann Institute of Science
Rehovot, Israel
Prof. Janet Shipley
Team Leader, Sarcoma Molecular Pathology,
The Institute of Cancer Research
London, UK
Prof. Viktor Umansky
German Cancer Research Center
(DKFZ)
Halle, Germany
Prof. Frédéric Paccaud
Directeur de l’Institut universitaire de médecine sociale et préventive (IUMSP).
Professeur d’épidémiologie et de santé publique,
Faculté de biologie et médecine de l’Université de Lausanne
Lausanne, Switzerland
Dr Nicolas Leupin
Chief Medical Officer
at Argenx
Zürich, Switzerland
Jean-Pierre ARMAND MD
Ceo&co founder pegascy
Senior Consultant Oncology
Early Drug and Therapeutic Innovation Department (DITEP)gustave roussy.
Université Paris-saclay
VP CSMO at Cancer Campus Grand Paris
Villejuif, France
Dr Audrey Brussel
Ex-patiente
Meudon, France